In this issue:
Leukaemia selection
Clofarabine in older AML
Retinoic acid/arsenic trioxide for APL
SCT donor source and outcomes in MDS
Ibrutinib in relapsed CLL
Early response predicts better outcomes in new CLL
Richter syndrome in CLL
Lymphoma selection
Treatment-related mortality in advanced Hodgkin’s lymphoma
Ibrutinib in relapsed/ refractory MCL
Second neoplasm risk in non-Hodgkin’s lymphoma
Consolidation autologous SCT in PTCL in first remission
Please login below to download this issue (PDF)